

IN THE SPECIFICATION:

Please amend the specification by inserting, after “frequently applied in the form of the base.” at page 4, line 2, and before “Surprisingly, it was now found ...” at page 4, line 4, the following:

Brief Description of the Drawings

Figure 1 illustrates a general procedure that can be used for the manufacture of fesoterodine base.

Figure 2 illustrates the in-vitro flux rate through human skin for the high purity free base of fesoterodine.

Figure 3 illustrates the in-vitro flux rate through mouse skin for the high purity free base of fesoterodine.

Figure 4 illustrates the typical structure of a monolithic TTS.